(Q36440050)

14 August 2017

The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia (English)

1 reference

14 August 2017

0 references

Ric Day

4

0 references

author name string

Christine Y Lu

series ordinal

1

1 reference

14 August 2017

Jan Ritchie

series ordinal

2

1 reference

14 August 2017

Ken Williams

series ordinal

3

1 reference

14 August 2017

20 December 2007

1 reference

Australia and New Zealand Health Policy

14 August 2017

1 reference

14 August 2017

4

1 reference

14 August 2017

26

1 reference

Creative Commons Attribution 2.0 Generic

14 August 2017

start time

1 December 2007

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2231358

Recent developments in targeting access to high cost medicines in Australia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2231358

Priority setting in hospitals: fairness, inclusiveness, and the problem of institutional power differences

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2231358

Qualitative methods in research on healthcare quality

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2231358

Qualitative research in health care. Analysing qualitative data

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2231358

Enhancing the quality and credibility of qualitative analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2231358

Access to high cost drugs in Australia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2231358

The ethics of Pharmaceutical benefit management.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2231358

Subsidised access to TNF alpha inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible?

21 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18096055

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The subsidy of pharmaceuticals in Australia: processes and challenges

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18096055

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1743-8462-4-26

1 reference

Dimensions Publication ID

14 August 2017

0 references

1 reference

14 August 2017

PubMed publication ID

18096055

1 reference